CN102137660A - 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 - Google Patents
冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 Download PDFInfo
- Publication number
- CN102137660A CN102137660A CN2009801333907A CN200980133390A CN102137660A CN 102137660 A CN102137660 A CN 102137660A CN 2009801333907 A CN2009801333907 A CN 2009801333907A CN 200980133390 A CN200980133390 A CN 200980133390A CN 102137660 A CN102137660 A CN 102137660A
- Authority
- CN
- China
- Prior art keywords
- trpm8
- regulator
- chemical compound
- receptor
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150111302 Trpm8 gene Proteins 0.000 title claims abstract description 54
- 102000003610 TRPM8 Human genes 0.000 title claims abstract description 51
- 229940041616 menthol Drugs 0.000 title claims abstract description 17
- 238000001514 detection method Methods 0.000 title description 3
- 230000035807 sensation Effects 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 37
- 102000005962 receptors Human genes 0.000 claims description 21
- 108020003175 receptors Proteins 0.000 claims description 21
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 8
- 239000004753 textile Substances 0.000 claims description 8
- 239000002917 insecticide Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000005022 packaging material Substances 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 3
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 239000000077 insect repellent Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 241000195940 Bryophyta Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010042496 Sunburn Diseases 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 208000029162 bladder disease Diseases 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- -1 polycyclic organic compound Chemical class 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 208000026533 urinary bladder disease Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000010220 ion permeability Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000006698 induction Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 18
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 235000019615 sensations Nutrition 0.000 description 12
- 239000011575 calcium Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000556 agonist Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 229960002180 tetracycline Drugs 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 239000000975 dye Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 239000002269 analeptic agent Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 2
- 102000003566 TRPV1 Human genes 0.000 description 2
- 101150016206 Trpv1 gene Proteins 0.000 description 2
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 229960004873 levomenthol Drugs 0.000 description 2
- 229930007503 menthone Natural products 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000004528 spin coating Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- RCORSHSFJCXHTF-UHFFFAOYSA-N 2-ethenyl-1,3-dioxan-5-ol Chemical compound OC1COC(C=C)OC1 RCORSHSFJCXHTF-UHFFFAOYSA-N 0.000 description 1
- MDVYIGJINBYKOM-UHFFFAOYSA-N 3-[[5-Methyl-2-(1-methylethyl)cyclohexyl]oxy]-1,2-propanediol Chemical compound CC(C)C1CCC(C)CC1OCC(O)CO MDVYIGJINBYKOM-UHFFFAOYSA-N 0.000 description 1
- CTMTYSVTTGVYAW-FRRDWIJNSA-N 5-[(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]oxy-5-oxopentanoic acid Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)CCCC(O)=O CTMTYSVTTGVYAW-FRRDWIJNSA-N 0.000 description 1
- 101100350964 Arabidopsis thaliana PANS1 gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 101150076566 CMR1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-OUBTZVSYSA-N Calcium-41 Chemical compound [41Ca] OYPRJOBELJOOCE-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
- 229940080309 TRPM8 agonist Drugs 0.000 description 1
- 229940123537 TRPM8 antagonist Drugs 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 102100034030 Transient receptor potential cation channel subfamily M member 8 Human genes 0.000 description 1
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000010221 calcium permeability Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000917 hyperalgesic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- HHVOOJDLCVOLKI-VWLOTQADSA-N methyl (2S)-2-(dibenzylamino)-3-(1H-indol-3-yl)propanoate Chemical compound C=1C=CC=CC=1CN([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)OC)CC1=CC=CC=C1 HHVOOJDLCVOLKI-VWLOTQADSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C13/00—Cream; Cream preparations; Making thereof
- A23C13/12—Cream preparations
- A23C13/125—Cream preparations in powdered, granulated or solid form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/88—Taste or flavour enhancing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/055—Organic compounds containing sulfur as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/16—Nitrogen-containing compounds
- C08K5/20—Carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/16—Nitrogen-containing compounds
- C08K5/34—Heterocyclic compounds having nitrogen in the ring
- C08K5/3412—Heterocyclic compounds having nitrogen in the ring having one nitrogen atom in the ring
- C08K5/3432—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/16—Nitrogen-containing compounds
- C08K5/34—Heterocyclic compounds having nitrogen in the ring
- C08K5/3442—Heterocyclic compounds having nitrogen in the ring having two nitrogen atoms in the ring
- C08K5/3462—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/36—Sulfur-, selenium-, or tellurium-containing compounds
- C08K5/45—Heterocyclic compounds having sulfur in the ring
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/322—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen
- D06M13/35—Heterocyclic compounds
- D06M13/355—Heterocyclic compounds having six-membered heterocyclic rings
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/322—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen
- D06M13/402—Amides imides, sulfamic acids
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/322—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen
- D06M13/402—Amides imides, sulfamic acids
- D06M13/408—Acylated amines containing fluorine atoms; Amides of perfluoro carboxylic acids
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/322—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen
- D06M13/402—Amides imides, sulfamic acids
- D06M13/418—Cyclic amides, e.g. lactams; Amides of oxalic acid
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/322—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen
- D06M13/402—Amides imides, sulfamic acids
- D06M13/432—Urea, thiourea or derivatives thereof, e.g. biurets; Urea-inclusion compounds; Dicyanamides; Carbodiimides; Guanidines, e.g. dicyandiamides
-
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H17/00—Non-fibrous material added to the pulp, characterised by its constitution; Paper-impregnating material characterised by its constitution
- D21H17/03—Non-macromolecular organic compounds
- D21H17/05—Non-macromolecular organic compounds containing elements other than carbon and hydrogen only
- D21H17/07—Nitrogen-containing compounds
-
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H17/00—Non-fibrous material added to the pulp, characterised by its constitution; Paper-impregnating material characterised by its constitution
- D21H17/03—Non-macromolecular organic compounds
- D21H17/05—Non-macromolecular organic compounds containing elements other than carbon and hydrogen only
- D21H17/09—Sulfur-containing compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
- A61K2800/244—Endothermic; Cooling; Cooling sensation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Textile Engineering (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Urology & Nephrology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及冷薄荷醇受体TRPM8的新调节剂,使用这些调节剂调节TRPM8受体的方法;所述调节剂用于诱导冷感觉的用途;以及使用这些调节剂制备的物品和工具。
Description
本发明涉及冷薄荷醇受体TRPM8的新型调节剂,使用这些调节剂调节TRPM8受体的方法;所述调节剂诱导冷感觉的用途;以及使用这些调节剂制备的物品和组合物。
发明背景
冷薄荷醇受体TRPM8(也称为冷膜受体(CMR)1)属于“瞬时受体电位离子通道”家族,在一类特定的神经元中表达,在细胞膜中形成空穴(在各种情况下4个单元结合形成四聚体),其选择性的允许Ca2+离子通过。所述蛋白具有6个跨膜结构域以及胞质C和N末端。低温(优选10-25℃)能刺激该受体,产生信号转导,所述信号被神经***理解为冷感觉。该受体在2002年在多篇出版物中首次被描述为冷觉受体(Peier AM等,感觉冷刺激和薄荷醇的TRP通道,2002Mar 8;108(5):705-15;McKemy DD等,冷受体的鉴定揭示了TRP通道在热感觉中的普遍作用,Nature.2002Mar 7;416(6876):52-8;Zuker CS.神经生物学:冷离子通道,Nature.2002Mar 7;416(6876):27-8)。
致冷的化合物,例如薄荷醇,很长时间以来在调味剂和芳香剂工业中具有重要作用,以产生新鲜和清洁感的结合。对于化合物薄荷醇来说,已显示其作为受体TRPM8的天然调节剂起作用(McKemy D.D.,Molecular Pain1,2005,16;McKemy D.D.,Nature416,2002,52-58;Peier A.M.,Cell108,2002,705-715;Dhaka A.,Annu.Rev.Neurosci.29,2006,135-161)。通过应用薄荷醇,激活TRPM8,使得Ca2+流入冷敏神经元中。产生的电信号最终被感知为冷感觉。薄荷醇浓度升高可导致刺激和麻醉效应。此外,许多出版物描述了具有类似效应的薄荷醇衍生物(英国专利1971#1315761;Watson H.R.,J.Soc.Cosmet.Chem.29,1978,185-200;Furrer S.M.,Chem.Percept.1,2008,119-126)。还有结构上与薄荷醇不相关的个别化合物也产生了显著的TRPM8调节效应,例如Icilin(Wei E.T.,J.Pharm.Pharmacol.35,1983,110-112;WO 2004/026840)、WS-23或专利申请WO 2007/019719中所列的化合物。
调节TRPM8受体和/或其昆虫中的类似物的物质的另一种效应是对昆虫的驱除作用(WO 2002/015692;WO 2004/000023、US 2004/0028714),其在抗肿瘤治疗(例如影响***肿瘤)、炎性疼痛/痛觉过敏的治疗中也具有活性,并且可用作TRPM8拮抗剂来有效治疗膀胱综合征或膀胱活动过度(Beck B.Cell Calcium,41,2007,285-294;Levine J.D.Bioch im.Biophys.Acta,Mol.Basis Dis.1772,2007,989-1003;Mukerji G.,BMC Urology6,2006,6;US 2003/0207904;US 2005/6893626,Dissertation Behrendt H.J.2004,Bochum;Lashinger E.S.R.Am.J.Physiol.Renal Physiol.Am J Physiol Renal Physiol.2008Jun 18.[在出版之前的电子版];PMID:18562636)。
然而,迄今为止许多TRPM8调节剂在效应强度、效应持续时间、皮肤/粘膜刺激、气味、味觉、溶解性和/或挥发性方面仍具有缺陷。
发明概述
因此,本发明的一个目的是鉴定调节TRPM8受体的新物质,其可用作迄今已知的调节剂的备选物。这些化合物还应当尤其适用于化妆品(例如护发、护肤、口腔护理)、营养品(饲料/食物)、纺织品、OTC产品(例如烧伤软膏)、药物(例如肿瘤治疗、膀胱虚弱)、包装领域或作为杀虫剂或驱虫剂。
附图说明:
图1显示了来自根据序列数据库登录号NM 024080的hTRPM8受体的(a)mRNA序列和(b)氨基酸序列。
图2显示了编码hTRPM8的质粒pInd_M8的载体图谱,其已用于转染HEK293细胞。
发明详述:
1.通用术语定义:
在文献中,″TRPM8″有多个同义词:TRPP8、LTRPC6、CMR1、MGC2849、瞬时受体电位阳离子通道亚家族M成员8。在本发明的背景中,涵盖所有的名称。该受体的所有功能性修饰也包括在内,例如尤其是剪接变体,亚型,例如TRPM8CRA_a、TRPM8CRA_b,和来自各种生物体例如人、小鼠、大鼠中的所有类似受体。不同受体的核苷酸和氨基酸序列是本身已知的,在序列数据库中列出。因此,例如hTRPM8的序列信息可以登录号NM_024080表示。
在本发明的内容中,“调节剂”是指能在体内和/或体外作为TRPM8受体激动剂和/或拮抗剂起作用的化合物。
在本文中适当的调节剂可仅作为拮抗剂或激动剂起作用,或同时作为拮抗剂和激动剂起作用,此时,产生激动效应或拮抗效应取决于选择的具体调节剂的浓度。
在本文中,“激动剂”是指介导TRPM8受体活化,由此诱导Ca2+进入冷敏神经元,从而介导冷感觉的化合物。相反,“拮抗剂”是指阻碍TRPM8受体活化的化合物。
本发明的介导物可通过可逆或不可逆、特异性或非特异性结合TRPM8受体分子发挥其作用。通常,与受体分子的结合通过离子和/或非离子的例如疏水作用而非共价性的发生。在本文中,“特异性的”包括与一种或多种不同的TRPM8受体分子(例如不同来源或不同亚型的TRPM8分子)排他性的相互作用。相反,“非特异性的”是指所述调节剂与多种不同功能和/或序列的受体分子相互作用,但是可产生对TRPM8所希望的受体激动和/或拮抗调节(如上文所述)。
2.优选的实施方案
本发明首先涉及体外或体内调节冷薄荷醇受体TRMP8的方法,尤其是人TRPM8受体,其中所述受体与至少一种选自多环有机化合物的化合物接触,所述化合物在使用重组表达人TRPM8受体的细胞进行的细胞活性测试中、特别是在标准条件下调节了这些细胞对Ca2+离子的通透性。
在该部分中,“标准条件”理解为表示使用经人TRPM8转化的HEK293细胞进行的实验,该细胞加载了钙敏感染料(例如Fluo-4AM,即氟-4-乙酰氧基甲基酯)后加入测试化合物,并检测颜色变化,实验过程在37℃进行,如下文实施例3所述,或参见Behrendt等(2004),见上文)。
特别的,所述调节化合物包含至少2个4-至7-元环,其各自独立地为碳环或杂环、单环或多环,其中在这些环中至少2个可任选稠合或螺连接。合适的环连接的其他非限制性实例包括环碳原子和/或环杂原子间的化学单键,通过2-6元碳桥连基团连接,其中各个碳原子可被诸如N、O或S的杂原子替换。此外,所述环和桥连基可任选携带取代基,所述取代基选自酮基、-OH、-SH、-CN、-NO2、-C1-6-烷基或C2-4-链烯基,其中在烷基或链烯基中,一个或多个H原子可被诸如F、Cl、Br或I的卤素替换。
在本文中碳环包含4、5、6或7个碳原子;除环碳原子外,杂环包括1-3个相同或不同的环杂原子,例如O、N和S原子。在本文中的环可以各自独立地是饱和的、单或多不饱和的,例如芳环。
本发明使用的调节剂对于细胞Ca2+通透性具有激动或拮抗效应。具体而言,所述调节剂是至少一种选自下表1中的式1-19的化合物。
表1:根据本发明的调节剂
其中化合物可以化学纯或富集形式存在,为单个立体异构体或立体异构体混合物形式。此外,所述化合物可以是不带电的或其盐形式,例如酸加成盐。官能团可任选被等价的化学基团替换;氟原子可被其他卤素原子,例如Cl、Br或I替换;氧原子(例如醚基)可被相应的硫基团替换,反之亦然;酮基团可被相应的亚硫酰基替换。上面具体描述的化合物是本身已知的化学物质,可商购或通过常规有机合成方法获得。
因此,例如下列化合物是已知的:
化合物1,CAS号:99602-94-5(3R-顺式)
化合物2,CAS号:165753-08-2
化合物3,CAS号:338771-57-6
化合物4,CAS号:878942-21-3
化合物5,CAS号:748783-13-3
如果修饰形式或衍生物也表现出需要的生物学活性(受体TRPM8的调节),那么它们也是功能类似物或功能等价化合物。
此外,本发明还包括使具体公开的物质与固相载体偶联的衍生物;本领域技术人员已知可选择多种相应的接头/间隔基团。所述衍生化可在偶联至固相前进行,或仅仅由偶联产生。
本发明还涉及TRPM8受体调节剂、尤其是激动剂在诱导人和/或动物的冷感觉,尤其是局部的,即皮肤或口腔的冷感觉中的用途,其中所述调节剂如上文所定义。当化合物在上述细胞活性测试中表现出对于hTRPM8的激动效应时,称为“诱导冷感觉”。
本发明还涉及TRPM8受体调节剂作为药物组合物的活性成分的用途,其中所述调节剂如上文所定义。
本发明还涉及TRPM8受体调节剂在***癌治疗、膀胱虚弱治疗或疼痛治疗中的用途,其中所述调节剂如上文所定义。
本发明还涉及TRPM8受体调节剂作为昆虫驱虫剂或杀虫剂的用途,其中所述调节剂如上文所定义。
本发明还涉及TRPM8受体调节剂在诱导对以多种加工形式(例如纤维、织物、模塑)的包装(例如由纸或塑料制成)的冷感觉中的用途,其中特别是在接触包装材料时,冷感觉变得显著,其中所述调节剂如上文所定义。在该部分内容中,所述物质可通过多种途径与包装材料相结合:例如通过旋转涂层、凹印、微囊化形式、直接引入到包装材料中(例如挤压)、调节剂的适当衍生物的共价偶联(通过适当的间隔物/接头基团来帮助分子与包装材料可逆或不可逆地结合)。本领域技术人员已知合适的方法。
本发明还涉及TRPM8受体调节剂在诱导纺织品的冷感觉中的用途,其中所述调节剂如上文所定义。在该部分内容中,所述物质可通过多种途径与纺织品相结合:例如通过旋转涂层、凹印、微囊化形式、直接引入到纺织品材料中(例如挤压)、调节剂的适当衍生物的共价偶联(通过适当的间隔物/接头基团来帮助分子与纺织品材料可逆或不可逆地结合)。本领域技术人员已知合适的方法。
本发明还涉及根据上述定义的物质本身作为TRPM8受体调节剂的用途,尤其是作为激动剂和/或拮抗剂。
本发明还涉及包含至少一种上述定义的化合物的组合物。特别的,所述组合物选自:
a)药物组合物,例如抗肿瘤组合物,治疗膀胱疾病的组合物,止痛剂;
b)食物,例如冰激凌、奶油冻、乳油、饮料、糕饼。
c)口腔护理组合物,例如牙膏、漱口水、口香糖、口气清新剂。
d)护肤或护发组合物,例如防晒霜、晒斑膏、洗剂、洗发水、硬膏、漱口剂、洗液、剃毛霜、调节剂、洗面奶、肥皂、沐浴乳和沐浴泡沫、止汗剂、除臭剂。
e)驱虫剂、杀虫剂。
除了各种具体组合物的常规成分外,所述组合物包含有效量的至少一种本发明的调节剂。在该部分内容中,“有效”表示所述调节剂的浓度足以带来需要的效应,例如药理学效果或感觉效应,例如在应用所述组合物(例如应用至皮肤)后冷的嗅觉效应。
任选地,根据本发明的化合物可与其他已知的活性成分组合,尤其是那些具有相同效应的。例如,可与已知的制冷化合物组合,例如薄荷醇、薄荷酮、N-乙基-p-薄荷烷甲酰胺(WS-3)、N-2,3-三甲基-2-异丙基丁酰胺(WS-23)、乳酸薄荷酯(ML)、薄荷酮甘油缩醛(MGA)、琥珀酸单薄荷酯戊二酸单薄荷酯、O-薄荷基甘油、N,N-二甲基琥珀酸酰胺薄荷酯。
本发明还涉及纺织品,例如衬衫、长裤、袜子、毛巾,其采用至少一种上述定义的化合物整理(finish)(尤其在表面上)。
本发明还涉及与至少一种上述定义的化合物结合的包装材料。
现参照下述非限制性的工作实施例来描述本发明。
实验部分:
实施例1-人TRPM8的克隆
人TRPM8受体克隆的起点是LnCaP cDNA文库。其例如可从商业获得(例如BioChain,Hayward,USA)或使用标准试剂盒从雄激素敏感的人***癌细胞系LnCaP(例如ATCC,CRL1740或ECACC,89110211)制备。
可使用标准方法PCR扩增和克隆编码TRPM8的序列(参见图1A;和http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=109689694)。通过这种方法分离的人TRPM8基因被用于制备质粒pInd_M8,其构建通过图2的质粒图谱进行说明。
或者,TRPM8基因也可通过合成制备。
实施例2-HEK293测试细胞的传代
制备稳定转染人TRPM8DNA(参见上述质粒pInd-M8)的HEK293细胞系作为测试细胞***。在本文中优选通过引入的质粒提供用四环素诱导TRPM8表达的HEK293。
本领域技术人员已知生产适当的测试细胞***的方法。例如,本发明使用的细胞的制备详情参见Behrendt H.J.等,Br.J.Pharmacol.141,2004,737-745或Behrendt的论文“Vergleichende funktionale Untersuchungendes Hitze-Capsaicin-Rezeptors(TRPV1)und des-Menthol-Rezeptors(TRPM8)in rekombinanten und nativen Zellsystemen”.[热辣椒碱受体(TRPV1)和冷薄荷醇受体(TRPM8)在重组和天然细胞***中的功能比较研究],参见:
http://www-brs.ub.ruhr-uni-bochum.de/netahtml/HSS/Diss/BehrendtHansJoerg/diss.pdf。
特别引用这些文献公开的内容。
实施例3-TRPM8调节剂的测定
采用与已描述在文献中的试验相当的试验,参见Behrendt H.J.等人,Br.J.Pharmacol.141,2004,737-745。受体的激动或拮抗通过Ca2+敏感性染料(例如FURA,Fluo-4等)来量化。根据其自身特点,激动剂使Ca2+信号增加,拮抗剂例如在薄荷醇存在下使Ca2+信号减少(各自通过染料Fluo-4检测,其具有由Ca2+导致的不同的荧光性质)。
a)试验方法:
首先,在细胞培养瓶中以本身已知的方法制备转化的HEK细胞的新鲜培养液。使用胰蛋白酶从细胞培养瓶上分离测试细胞HEK293-TRPM8,按每100μl培养基40000细胞/孔接种在96孔板中(Greiner#655948聚-D-赖氨酸-涂覆)。为诱导受体TRPM8,向生长培养基中加入四环素(DMEM/HG,10%无四环素FCS,4mM L-谷氨酰胺,15μg/ml灭菌素,100μg/ml潮霉素B,1μg/ml四环素)。第二天,细胞加载Fluo-4AM染料,进行试验。使用下列步骤:
-在每100μl培养基(DMEM/HG,10%无四环素FCS,4mM L-谷氨酰胺,15μg/ml灭菌素,100μg/ml潮霉素B,1μg/ml四环素)中各自加入100μl/孔的染料溶液Ca-4kit(RB 141,Molecular Devices)。
-在培养箱中孵育30分钟/37℃/5%CO2,30分钟/RT。
-制备供试物质(在200μl HBSS缓冲液中,不同浓度)和阳性对照(不同浓度的薄荷醇、icilin和离子霉素,在200μl HBSS缓冲液中)和阴性对照(仅200μl HBSS缓冲液)。
-以50μl/孔的量加入试验物质,在485nm激发、520nm发射测定荧光的变化(例如测定仪器FLIPR,Molecular Devices或NovoStar,BMG),评价不同物质/浓度的效果,确定EC50值。
试验物质以浓度0.1-200μM一式三份进行测定。通常将化合物保存在DMSO溶液中,稀释至最大DMSO浓度2%进行测定。
b)试验结果
本发明调节剂测定的EC50值总结于下表2。
表2:试验物质对于人受体TRPM8的活性
该评价令人惊讶的发现,首次能够制备结构显著不同于已知的TRPM8受体激动剂,例如(-)薄荷醇、icilin和其他Behrendt H.J.等在Br.J.Pharmacol.141,2004,737-745(参见表1)中描述的激动剂的TRPM8受体激动剂,并且,在某些情况中其具有比(-)薄荷醇更好的活性,或与icilin效果相当。
实施例4-漱口剂的制备
制备下列组成的漱口剂:
乙醇95% 177ml
山梨醇70% 250g
根据表2的TRPM8激动剂,
其为1%的乙醇溶液 50ml
薄荷油 0.30g
水杨酸甲酯 0.64g
桉叶醇 0.922g
麝香草酚 0.639g
苯甲酸 1.50g
F127,
非离子表面活性剂 5.00g
糖精钠 0.60g
柠檬酸钠 0.30g
柠檬酸 0.10g
水 适量,至1升
为制备漱口剂,以所述量混合上述成分。
本文特别参考所引用的文献资源的公开内容。
Claims (15)
1.体外或体内调节冷薄荷醇受体TRMP8的方法,其中所述受体与至少一种选自多环有机化合物的化合物接触,所述化合物在使用重组表达人TRPM8受体的细胞进行的细胞活性测试中调节了这些细胞对Ca2+离子的通透性。
2.权利要求1的方法,其中所述调节化合物具有至少2个4-至7-元环,其各自独立地为碳环或杂环、单环或多环,其中在这些环中至少2个可任选地稠合。
3.权利要求1或2的方法,其中所述调节剂对于细胞Ca2+离子通透性具有激动或拮抗效应。
5.TRPM8受体调节剂在诱导人和/或动物的冷感觉中的用途,其中所述调节剂如权利要求1-4任一项所定义。
6.TRPM8受体调节剂作为药物组合物活性成分的用途,其中所述调节剂如权利要求1-4任一项所定义。
7.TRPM8受体调节剂在***癌治疗、膀胱虚弱治疗或疼痛治疗中的用途,其中所述调节剂如权利要求1-4任一项所定义。
8.TRPM8受体调节剂作为昆虫驱虫剂或杀虫剂的用途,其中所述调节剂如权利要求1-4任一项所定义。
9.TRPM8受体调节剂在诱导包装的冷感觉中的用途,其中所述调节剂如权利要求1-4任一项所定义。
10.TRPM8受体调节剂在诱导纺织品的冷感觉中的用途,其中所述调节剂如权利要求1-4任一项所定义。
11.根据权利要求1-4任一项的定义的物质,其用作TRPM8受体调节剂。
12.组合物,其包含至少一种如权利要求1-4任一项所述的化合物。
13.权利要求12的组合物,选自:
a)药物组合物,例如抗肿瘤剂,膀胱疾病治疗剂,止痛剂;
b)食物,例如冰激凌、奶油冻、乳油、饮料、糕饼;
c)口腔护理组合物,例如牙膏、漱口水、口香糖;
d)护肤或护发组合物,例如防晒霜、晒斑膏、洗剂、洗发水、硬膏;
e)昆虫驱虫剂、杀虫剂。
14.纺织品,例如衬衫、长裤、袜子、毛巾,其采用至少一种如权利要求1-4任一项所述的化合物整理。
15.与至少一种如权利要求1-4任一项所述的化合物结合的包装材料。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010795118.3A CN111803478B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
CN201710396933.0A CN107375284B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
CN201410336374.0A CN104147016B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08162997.4 | 2008-08-26 | ||
EP08162997 | 2008-08-26 | ||
PCT/EP2009/061019 WO2010026094A1 (de) | 2008-08-26 | 2009-08-26 | Nachweis und verwendung niedermolekularer modulatoren des kälte-menthol-rezeptors trpm8 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410336374.0A Division CN104147016B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
CN201710396933.0A Division CN107375284B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
CN202010795118.3A Division CN111803478B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102137660A true CN102137660A (zh) | 2011-07-27 |
CN102137660B CN102137660B (zh) | 2014-08-13 |
Family
ID=41119517
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710396933.0A Active CN107375284B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
CN201410336374.0A Active CN104147016B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
CN200980133390.7A Active CN102137660B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
CN202010795118.3A Active CN111803478B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710396933.0A Active CN107375284B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
CN201410336374.0A Active CN104147016B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010795118.3A Active CN111803478B (zh) | 2008-08-26 | 2009-08-26 | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8710096B2 (zh) |
EP (4) | EP2349239B1 (zh) |
JP (3) | JP5591238B2 (zh) |
CN (4) | CN107375284B (zh) |
CA (4) | CA3044178C (zh) |
ES (3) | ES2828974T3 (zh) |
WO (1) | WO2010026094A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102844386A (zh) * | 2009-11-20 | 2012-12-26 | 西姆莱斯股份公司 | 生理学清凉的活性成分以及含有这类活性成分的物质的用途 |
CN108473484A (zh) * | 2015-10-01 | 2018-08-31 | 赛诺米克斯公司 | 可用作trpm8调节剂的化合物 |
CN111343963A (zh) * | 2017-08-31 | 2020-06-26 | 巴斯夫欧洲公司 | 生理清凉活性成分的用途以及包含此类活性成分的组合物 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2349239B1 (de) | 2008-08-26 | 2017-11-15 | Basf Se | Nachweis und verwendung niedermolekularer modulatoren des kälte-menthol-rezeptors trpm8 |
MY182666A (en) * | 2010-11-05 | 2021-01-28 | Senomyx Inc | Compounds useful as modulators of trpm8 |
EP2497458A1 (en) | 2011-03-08 | 2012-09-12 | B.R.A.I.N. Biotechnology Research And Information Network AG | Small molecule modulators of the cold and menthol receptor TRPM8 |
EP2758041B1 (de) | 2011-09-20 | 2021-01-13 | Basf Se | Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung |
US20130251647A1 (en) | 2011-09-20 | 2013-09-26 | Basf Se | Low molecular weight modulators of the cold menthol receptor trpm8 and use thereof |
JP2013155141A (ja) * | 2012-01-31 | 2013-08-15 | Mikimoto Pharmaceut Co Ltd | 化粧料 |
US20130273619A1 (en) | 2012-04-16 | 2013-10-17 | Basf Se | Process for the Preparation of (3E, 7E)-Homofarnesol |
EP2931225B1 (de) * | 2012-12-12 | 2021-03-31 | Symrise AG | Kühlende zubereitungen |
JP6882144B6 (ja) * | 2012-12-12 | 2021-06-23 | シムライズ アーゲー | 組成物および化粧品組成物 |
CA2966345A1 (en) * | 2014-10-31 | 2016-05-06 | Avent, Inc. | Method and articles for inhibiting bladder contractions |
KR101624339B1 (ko) | 2014-12-16 | 2016-05-25 | 남우현 | Trpm8 저온수용체 단백질 활성화가 우수한 탈모방지 샴푸 |
WO2016188932A2 (en) | 2015-05-22 | 2016-12-01 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Combination compositions and their use in methods for treating obesity and obesity-related disorders |
WO2019021191A1 (en) | 2017-07-26 | 2019-01-31 | Tgx Soft Chew, Llc | STARCH-FREE MOUTH PRODUCT FOR VETERINARY APPLICATIONS |
WO2022105986A1 (de) | 2020-11-17 | 2022-05-27 | Symrise Ag | Neue kühlstoffe und zubereitungen, die diese enthalten |
WO2023143741A1 (de) | 2022-01-28 | 2023-08-03 | Symrise Ag | Neue kühlstoffe und zubereitungen, die diese enthalten |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3699323A (en) | 1970-12-23 | 1972-10-17 | Ibm | Error detecting and correcting system and method |
SU636236A1 (ru) | 1976-05-25 | 1978-12-05 | Институт Биоорганической Химии Ан Белорусской Сср | Производные 8-аза-16-оксагонана, обладающие противоспалительным действием и способ их получени |
RU704083C (ru) | 1978-07-05 | 1993-10-30 | Институт биоорганической химии АН БССР | Производные D-гомо-8-азагонана, обладающие противовоспалительной, мембраностабилизирующей и антикоагул ционной активностью |
SU704082A1 (ru) | 1978-07-05 | 1989-10-23 | Институт биоорганической химии АН БССР | Производные 8,16-диазагонана, обладающие противовоспалительной активностью и мембранозащитным действием |
SU776048A1 (ru) * | 1979-06-05 | 1983-09-23 | Институт Бисорганической Химии Ан Бсср | Производные 8-аза-16-оксагона-17-онов, про вл ющие противовоспалительную,мембраностабилизирующую и антифибринолитическую активность,и способ их получени |
CH651445A5 (en) | 1982-07-28 | 1985-09-30 | Ciba Geigy Ag | Composition and method for the selective control of weeds in transplanted rice or rice which is sown in water |
EP0436729A4 (en) * | 1989-08-01 | 1991-09-11 | Kanebo, Ltd. | Microcapsule, treatment liquid containing microcapsules, and textile structure having microcapsules stuck thereto |
JP3394596B2 (ja) * | 1994-05-23 | 2003-04-07 | 日本テトラパック株式会社 | 包装容器 |
AU7933098A (en) * | 1997-06-25 | 1999-01-04 | Yamanouchi Pharmaceutical Co., Ltd. | Novel amidrazone derivatives having antifungal activity |
NO306533B1 (no) | 1998-04-21 | 1999-11-22 | Gunnar Volden | Insektmiddel |
JP2000302760A (ja) * | 1999-02-17 | 2000-10-31 | Hokuriku Seiyaku Co Ltd | 2−メルカプトキノリン誘導体 |
WO2002000590A1 (en) | 2000-06-23 | 2002-01-03 | California Institute Of Technology | Synthesis of functionalized and unfunctionalized olefins via cross and ring-closing metathesis |
US20040028714A1 (en) | 2000-08-24 | 2004-02-12 | Philippe Blondeau | Composition having insect repellent characteristics |
US6919348B2 (en) * | 2002-05-02 | 2005-07-19 | Edward T. Wei | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith |
GB0214342D0 (en) | 2002-06-21 | 2002-07-31 | Givaudan Sa | Insect repellents |
US7247741B2 (en) * | 2005-01-21 | 2007-07-24 | Ptc Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
DE10234876A1 (de) * | 2002-07-25 | 2004-02-05 | Bayer Cropscience Gmbh | 4-Trifluormethylpyrazolyl substituierte Pyridine und Pyrimidine |
GB0221697D0 (en) * | 2002-09-18 | 2002-10-30 | Unilever Plc | Novel compouds and their uses |
DE10259619A1 (de) * | 2002-12-18 | 2004-07-08 | Metagen Pharmaceuticals Gmbh | Verwendung einer TRPM8 aktivierenden Substanz zur Tumorbehandlung |
US6893626B2 (en) | 2003-02-18 | 2005-05-17 | Edward T. Wei | Compositions for TRP-M8 binding and radioreceptor methods therewith |
US7169377B2 (en) * | 2003-10-15 | 2007-01-30 | Wei Edward T | Radioligands for the TRP-M8 receptor and methods therewith |
JP2007527913A (ja) * | 2004-03-08 | 2007-10-04 | ワイス | イオンチャンネルモジュレーター |
CN1964988A (zh) * | 2004-04-08 | 2007-05-16 | 詹森药业有限公司 | 犬的冷和薄荷醇敏感受体1 |
JP2007532669A (ja) * | 2004-04-13 | 2007-11-15 | イカジェン インコーポレイテッド | カリウムイオンチャネル調節剤としての多環式ピリミジン |
US20050250836A1 (en) * | 2004-05-03 | 2005-11-10 | Pfizer Inc | Inhibitors of checkpoint kinases (Wee1 and Chk1) |
EP1802600A1 (en) | 2004-10-13 | 2007-07-04 | Bayer HealthCare AG | Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonits for the treatment of urological disorders |
WO2006097337A2 (en) * | 2005-03-18 | 2006-09-21 | Onepharm Gmbh | 11β-HYDROXYSTEROID DEHYDROGENASES |
WO2007017093A1 (en) * | 2005-08-04 | 2007-02-15 | Bayer Healthcare Ag | Substituted 2-benzyloxy-benzoic acid amide derivatives |
BRPI0616821B1 (pt) | 2005-08-15 | 2022-06-07 | Givaudan Sa | Método para proporcionar um efeito refrescante em um produto e produto possuindo um efeito refrescante |
ATE443046T1 (de) | 2005-10-25 | 2009-10-15 | Givaudan Sa | Organische verbindungen |
WO2007080109A1 (en) * | 2006-01-16 | 2007-07-19 | Bayer Healthcare Ag | Substituded benzyloxy-phenylmethylurea derivatives |
PL1986622T3 (pl) * | 2006-02-15 | 2014-03-31 | Dendreon Pharmaceuticals Inc | Drobnocząsteczkowe modulatory aktywności TRP-P8 |
GB0615136D0 (en) * | 2006-07-29 | 2006-09-06 | Univ Edinburgh | Induction of analgesia in neuropathic pain |
EP1913976A1 (de) | 2006-10-18 | 2008-04-23 | Symrise GmbH & Co. KG | N-alpha-(Menthancarbonyl)aminosäureamide und deren Verwendung als physiologische Kühlwirkstoffe |
EP1958627A3 (de) | 2007-01-04 | 2010-09-01 | Symrise GmbH & Co. KG | Verwendung bestimmter Menthyl-3-oxocarbonsäureester als physiologisch wirksame Kühlsubstanzen |
ES2395682T3 (es) | 2007-08-20 | 2013-02-14 | Symrise Ag | Derivados de ácido oxálico y su uso como principios activos refrescantes fisiológicos |
WO2009064388A2 (en) | 2007-11-09 | 2009-05-22 | Liu Jun O | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
WO2010010435A2 (en) | 2008-07-22 | 2010-01-28 | Glenmark Pharmaceutical S.A. | Fused oxazole and thiazole derivatives as trpms modulators |
EP2349239B1 (de) | 2008-08-26 | 2017-11-15 | Basf Se | Nachweis und verwendung niedermolekularer modulatoren des kälte-menthol-rezeptors trpm8 |
-
2009
- 2009-08-26 EP EP09782234.0A patent/EP2349239B1/de active Active
- 2009-08-26 EP EP16175305.8A patent/EP3115045B1/de active Active
- 2009-08-26 ES ES16175305T patent/ES2828974T3/es active Active
- 2009-08-26 CN CN201710396933.0A patent/CN107375284B/zh active Active
- 2009-08-26 EP EP19214768.4A patent/EP3698779A1/de active Pending
- 2009-08-26 CN CN201410336374.0A patent/CN104147016B/zh active Active
- 2009-08-26 ES ES09782234.0T patent/ES2659421T3/es active Active
- 2009-08-26 CN CN200980133390.7A patent/CN102137660B/zh active Active
- 2009-08-26 CN CN202010795118.3A patent/CN111803478B/zh active Active
- 2009-08-26 JP JP2011524370A patent/JP5591238B2/ja active Active
- 2009-08-26 CA CA3044178A patent/CA3044178C/en active Active
- 2009-08-26 CA CA2937196A patent/CA2937196C/en active Active
- 2009-08-26 CA CA2937195A patent/CA2937195C/en active Active
- 2009-08-26 CA CA2734682A patent/CA2734682C/en active Active
- 2009-08-26 ES ES16175302T patent/ES2828975T3/es active Active
- 2009-08-26 WO PCT/EP2009/061019 patent/WO2010026094A1/de active Application Filing
- 2009-08-26 EP EP16175302.5A patent/EP3103447B1/de active Active
- 2009-08-26 US US13/060,323 patent/US8710096B2/en active Active
-
2014
- 2014-03-12 US US14/206,182 patent/US9346823B2/en active Active
- 2014-07-29 JP JP2014153389A patent/JP5795107B2/ja active Active
-
2015
- 2015-08-11 JP JP2015158967A patent/JP5956036B2/ja active Active
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102844386A (zh) * | 2009-11-20 | 2012-12-26 | 西姆莱斯股份公司 | 生理学清凉的活性成分以及含有这类活性成分的物质的用途 |
US9718839B2 (en) | 2009-11-20 | 2017-08-01 | Symrise Ag | Use of physiological cooling active ingredients, and agents containing such active ingredients |
US10584134B2 (en) | 2009-11-20 | 2020-03-10 | Symrise Ag | Use of physiological cooling active ingredients, and agents containing such active ingredients |
CN111053775A (zh) * | 2009-11-20 | 2020-04-24 | 西姆莱斯股份公司 | 生理学清凉的活性成分以及含有这类活性成分的物质的用途 |
CN111053775B (zh) * | 2009-11-20 | 2023-08-18 | 西姆莱斯股份公司 | 生理学清凉的活性成分以及含有这类活性成分的物质的用途 |
CN108473484A (zh) * | 2015-10-01 | 2018-08-31 | 赛诺米克斯公司 | 可用作trpm8调节剂的化合物 |
CN108473484B (zh) * | 2015-10-01 | 2021-06-29 | 弗门尼舍公司 | 可用作trpm8调节剂的化合物 |
CN111343963A (zh) * | 2017-08-31 | 2020-06-26 | 巴斯夫欧洲公司 | 生理清凉活性成分的用途以及包含此类活性成分的组合物 |
US11434220B2 (en) | 2017-08-31 | 2022-09-06 | Basf Se | Use of physiological cooling active ingredients, and compositions comprising such active ingredients |
CN111343963B (zh) * | 2017-08-31 | 2023-09-12 | 巴斯夫欧洲公司 | 生理清凉活性成分的用途以及包含此类活性成分的组合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102137660B (zh) | 冷薄荷醇受体trpm8的低分子量调节剂的检测和用途 | |
CN104918599B (zh) | 用于减少trpa1和trpv1感觉的组合物 | |
CN105764571B (zh) | 用于递送口腔舒适感的组合物 | |
JP2012153617A (ja) | 冷感増強剤 | |
Diomede | The soothing effect of menthol, eucalyptol and high-intensity cooling agents | |
JP5927048B2 (ja) | Trpv3活性化剤 | |
JP5820642B2 (ja) | Trpv3活性化剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |